Advertisement
Canada markets open in 8 hours 44 minutes

  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CAD/USD

    0.7304
    +0.0006 (+0.08%)
     

  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     

  • Bitcoin CAD

    88,011.12
    -3,394.31 (-3.71%)
     

  • CMC Crypto 200

    1,386.92
    -37.18 (-2.61%)
     

  • GOLD FUTURES

    2,325.10
    -13.30 (-0.57%)
     

  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     

  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     

  • NASDAQ futures

    17,461.00
    -203.50 (-1.15%)
     

  • VOLATILITY

    15.97
    +0.28 (+1.78%)
     

  • FTSE

    8,040.38
    -4.43 (-0.06%)
     

  • NIKKEI 225

    37,706.50
    -753.58 (-1.96%)
     

  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Stocks in play: Resverlogix Corp.

Baystreet.ca

Announced today the publishing of an article titled: "Bromodomain and extraterminal protein inhibitor, apabetalone (RVX-208), reduces ACE2 expression and attenuates SARS-CoV-2 infection in vitro", in Biomedicines, a high-impact scientific journal. The previously announced findings , made in collaboration with Dr. Dalia ElGamal’s research group at the University of Nebraska Medical Center (UNMC), Omaha, Nebraska, have completed the peer-review process. Resverlogix Corp. shares T.RVX are trading up $0.02 at $0.89.

Read: